WeVote
Log In

Bill

Bill

S 1478

Grants peace officer status to officers and members of the security force of Arnot Health, Inc.

2025 Regular Session Introduced by Tom O'Mara

Note on source material- The materials you supplied contain mixed and conflicting metadata (a federal-sounding “Countering Wrongful Detention Act of 2025,” U.S. Senate committee ac

REFERRED TO CODES
0
WeVote Research Nonpartisan
Bill Summary · S 1478

Note on source material
- The materials you supplied contain mixed and conflicting metadata (a federal-sounding “Countering Wrongful Detention Act of 2025,” U.S. Senate committee actions, and a Massachusetts Senate bill text). This summary focuses on the actual bill text included in the packet titled “An Act to reduce the risks associated with allergic reactions” (Massachusetts Senate No. 1478, presented by Sen. William N. Brownsberger), because that text is the substantive legislation provided.

Bill at a glance
- Bill number: Senate No. 1478 (Massachusetts)
- Short title in text: An Act to reduce the risks associated with allergic reactions
- Principal sponsor (in text): William N. Brownsberger (Suffolk and Middlesex)
- Key action required: Department of Public Health (DPH) to adopt regulations
- Regulatory compliance deadline: DPH must adopt regulations no later than 180 days after enactment

Purpose and intent
- Increase access to epinephrine auto‑injectors (EAI, “epi‑pens”) in businesses and other entities to reduce morbidity and mortality from severe allergic reactions (anaphylaxis), while providing training standards, reporting, and limited liability protections to encourage broader availability.

Key provisions
1. New statutory section
- Inserts a new Section 245 into Chapter 111 of the Massachusetts General Laws authorizing DPH to promulgate regulations allowing businesses/entities to be prescribed and to maintain epinephrine auto‑injectors for two main purposes:
a) Provide an EAI for immediate self‑administration to any individual an employee/agent believes in good faith may be experiencing anaphylaxis, regardless of whether that person has a prescription or known allergy.
b) Allow trained employees/designated individuals/agents to administer an EAI after completing DPH‑required training.

  1. Remote authorization for untrained lay administration

    • Businesses may store EAIs in a locked/secure container and make them available to untrained individuals for administration if remote authorization is obtained from a licensed physician or nurse practitioner via audio/video or similar electronic communication following a consultation. Such consultation is not to be treated as telemedicine for regulatory purposes.

  2. Liability and scope

    • Provides immunity from ordinary‑negligence liability for businesses, employees, designated agents, prescribers, and trainers acting in compliance with the section. This immunity does not extend to gross, willful, or wanton negligence.
    • Explicitly states administration under this authority is not the practice of medicine.

  3. Regulatory requirements (DPH to adopt within 180 days)

    • Incident reporting: Businesses acquiring EAIs must submit incident reports on DPH‑developed forms for each severe allergic reaction or EAI administration on their premises.
    • Annual report: DPH must compile, summarize, analyze incident reports and publish an annual report.
    • Training standards: DPH must establish detailed standards for training (may be online) that include:
      • Recognition of anaphylaxis symptoms,
      • Storage and administration procedures for EAIs,
      • Emergency follow‑up procedures.
      • Trainers must be licensed physicians/nurse practitioners or nationally recognized organizations approved by DPH.

  4. Optional certification program

    • DPH may create a certification program to recognize businesses that comply with the act and maintain an “allergy‑friendly” environment.

Who is affected
- Businesses and other entities that choose to acquire EAIs
- Employees, designated individuals, and agents who may be trained to administer EAIs
- Members of the public (customers, visitors, clients) who may experience allergic reactions
- Licensed physicians and nurse practitioners who prescribe or remotely authorize EAIs
- DPH (rulemaking, oversight, incident data collection, reporting, optional certification)

Potential impacts
- Likely to increase on‑site availability of EAIs and speed of first response to anaphylaxis outside clinical settings, which could reduce severe outcomes and deaths from allergic reactions.
- Imposes reporting and training compliance burdens on participating businesses and creates a DPH administrative role (rulemaking, incident aggregation, certification).
- Limited liability protection may encourage adoption while maintaining protection against gross or willful misconduct.

Procedural status and sponsors (from provided materials)
- Filed: January 8, 2025 (Senate docket entry in materials)
- Presented by: William N. Brownsberger
- Petitioners listed: William N. Brownsberger and Patrick Joseph Kearney (4th Plymouth)
- Committee referral in provided text: Referred to the committee on Public Health (per text); the packet also contains inconsistent committee/action items likely from other bills—those should be verified against official legislative records.

If you want, I can:
- Produce a short one‑page brief emphasizing compliance steps for businesses (training checklist, reporting steps), or
- Check the official Massachusetts legislative website for current procedural status and reconcile the inconsistent action history.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.